Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

COGT

Cogent Biosciences Inc

Dec 24 • 01:30PM ET

7.86

Dollar change +0.10
Percentage change 1.29	%

Healthcare • Biotechnology • USA • NASD

Peers: BLUE VRTX BEAM CRSP BPMC NTLA GILD EDIT ALLO FATE

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA DWAS VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.48	Insider Own	19.50%	Shs Outstand	110.46M	Perf Week	-4.03%
Market Cap	868.23M	Forward P/E	-	EPS next Y	-2.31	Insider Trans	0.00%	Shs Float	88.93M	Perf Month	-13.91%
Income	-242.30M	PEG	-	EPS next Q	-0.59	Inst Own	91.35%	Short Float	8.21%	Perf Quarter	-27.76%
Sales	0.00M	P/S	-	EPS this Y	-0.41%	Inst Trans	6.76%	Short Ratio	5.27	Perf Half Y	-2.96%
Book/sh	1.85	P/B	4.25	EPS next Y	4.93%	ROA	-65.53%	Short Interest	7.30M	Perf Year	36.93%
Cash/sh	3.04	P/C	2.59	EPS next 5Y	-	ROE	-78.47%	52W Range	4.28 - 12.61	Perf YTD	33.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.33%	ROI	-73.21%	52W High	-37.67%	Beta	1.74
Dividend TTM	-	Quick Ratio	6.44	Sales past 5Y	-6.78%	Gross Margin	-	52W Low	83.64%	ATR (14)	0.60
Dividend Ex-Date	-	Current Ratio	6.44	EPS Y/Y TTM	-5.88%	Oper. Margin	-	RSI (14)	33.37	Volatility	7.30% 7.20%
Employees	164	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.55	Target Price	16.80
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	0.23%	Payout	-	Rel Volume	0.39	Prev Close	7.76
Sales Surprise	-	EPS Surprise	-13.03%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	1.38M	Price	7.86
SMA20	-10.04%	SMA50	-21.01%	SMA200	-12.30%	Trades		Volume	537,249	Change	1.29%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-24	Downgrade	Needham	Buy → Hold
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral	$14 → $8
Feb-08-24	Initiated	Citigroup	Buy	$11
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral	$5
Dec-08-23	Initiated	JP Morgan	Overweight	$18
Apr-28-23	Initiated	Robert W. Baird	Outperform	$20
Mar-27-23	Resumed	H.C. Wainwright	Buy	$28
Dec-14-22	Initiated	Needham	Buy	$24
Jun-28-22	Initiated	Guggenheim	Buy	$15
Oct-11-21	Initiated	H.C. Wainwright	Buy	$25
Jun-09-21	Resumed	Jefferies	Buy	$20
Dec-23-20	Initiated	Piper Sandler	Overweight	$22
Oct-14-20	Initiated	Ladenburg Thalmann	Buy	$4

Show Previous Ratings

Dec-09-24 07:00AM	Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients (GlobeNewswire) +8.77%
Dec-08-24 12:00PM	Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Nov-05-24 09:00AM	Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire) -15.84%
Oct-23-24 07:00AM	Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-09-24 08:03AM	Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target (Insider Monkey)
08:00AM	Loading…
Sep-03-24 08:00AM	Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis (GlobeNewswire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-06-24 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-28-24 09:18AM	Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting (Zacks)
Jun-27-24 08:00AM	Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial (GlobeNewswire)
Jun-14-24 07:30AM	Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire) -6.18%
May-23-24 05:05PM	Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer (GlobeNewswire) -6.72% +9.75%
05:01PM	Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting (GlobeNewswire)
May-07-24 01:52PM	COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Cogent Biosciences Reports First Quarter 2024 Financial Results (GlobeNewswire)
09:00AM	Loading…
Apr-09-24 09:00AM	Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor (GlobeNewswire) +7.21%
Mar-13-24 07:06AM	5 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Feb-28-24 04:32AM	COGT Reports Full Year 2023 Financial Results and Business Highlights (GuruFocus.com)
Feb-26-24 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-22-24 02:30PM	Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (GlobeNewswire)
Feb-14-24 07:00AM	Cogent Biosciences Announces Oversubscribed $225 Million Private Placement (GlobeNewswire) +59.34%
Feb-05-24 09:00AM	Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting (GlobeNewswire) +18.75%
Jan-09-24 08:00AM	Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics (GlobeNewswire) -7.73%
Jan-02-24 08:00AM	Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.12%
Dec-11-23 07:55AM	Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire) -53.01%
Dec-09-23 01:30PM	Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire)
Dec-07-23 09:00AM	Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3K inhibitor programs at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-04-23 08:00AM	Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-29-23 08:00AM	Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium (GlobeNewswire) +5.67%
Nov-02-23 09:00AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire)
12:30PM	Loading…
Oct-14-23 12:30PM	Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-13-23 08:51AM	After losing 15% in the past year, Cogent Biosciences, Inc. (NASDAQ:COGT) institutional owners must be relieved by the recent gain (Simply Wall St.)
Aug-08-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results (GlobeNewswire) +7.62%
Jul-10-23 07:35PM	Analysts Say These 2 Stocks Are Their Top Picks for the Rest of 2023 (TipRanks)
Jun-09-23 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock (GlobeNewswire)
Jun-07-23 09:00AM	Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference (GlobeNewswire) -10.21%
Jun-06-23 08:25PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock (GlobeNewswire)
04:05PM	Cogent Biosciences Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-03-23 02:15PM	Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
May-23-23 08:00AM	Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
May-09-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-17-23 09:00AM	Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis (GlobeNewswire) +6.62%
Apr-12-23 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire) -5.74%
Mar-14-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +7.54%
Feb-01-23 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Jan-11-23 11:03AM	Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-09-23 08:00AM	Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics (GlobeNewswire)
Jan-05-23 08:00AM	Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-22 05:30PM	Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Dec-05-22 08:00AM	Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (GlobeNewswire)
Nov-28-22 04:15PM	Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development (GlobeNewswire) +6.14%
Nov-14-22 07:00AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-09-22 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire) -5.63%
Nov-03-22 09:05AM	Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire)
Oct-26-22 07:00AM	Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting (GlobeNewswire)
Aug-14-22 12:21PM	2 Monster Growth Stocks That Could Reach New Highs (TipRanks)
Aug-09-22 07:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 11:22AM	Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth (Simply Wall St.) +12.58%
Jun-20-22 11:09AM	Is Cogent Biosciences, Inc. (NASDAQ:COGT) Popular Amongst Institutions? (Simply Wall St.)
Jun-16-22 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -6.47% +17.82%
Jun-13-22 09:48PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants (GlobeNewswire) +11.05%
06:00AM	Cogent Biosciences Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-10-22 07:00AM	Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire) +58.67%
Jun-06-22 10:15AM	Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET (GlobeNewswire)
Jun-02-22 08:00AM	Cogent Biosciences Announces Annual Meeting of Stockholders (GlobeNewswire)
May-12-22 10:00AM	Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress (GlobeNewswire) -7.11%
May-10-22 07:00AM	Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results (GlobeNewswire) -8.29%
May-06-22 08:00AM	Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium (GlobeNewswire)
Apr-11-22 07:00AM	Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event (GlobeNewswire)
Mar-29-22 07:00AM	Cogent Biosciences to Host Virtual R&D Investor Event (GlobeNewswire) +5.79%
Mar-15-22 07:00AM	Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-08-22 05:10PM	Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022 (GlobeNewswire)
Feb-01-22 05:29AM	Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jan-05-22 07:00AM	Cogent Biosciences Provides 2022 Corporate Guidance (PR Newswire)
Nov-22-21 07:00AM	Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference (PR Newswire) -6.12%
Nov-10-21 07:00AM	Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results (PR Newswire)
Nov-02-21 07:00AM	Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021 (PR Newswire)
Oct-29-21 09:46AM	Hedge Funds Are Dumping Cogent Biosciences, Inc. (COGT) (Insider Monkey)
Oct-12-21 07:59PM	2 Strong Buy Stocks Under $10 With Over 100% Upside Potential (TipRanks) +10.94%
Oct-07-21 09:00AM	Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain Penetration (PR Newswire)
Oct-01-21 07:00AM	Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference (PR Newswire)
Aug-16-21 07:00AM	Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results (PR Newswire)
Jul-27-21 07:00AM	Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021 (PR Newswire)
Jul-13-21 11:11AM	Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy? (Insider Monkey)
Jun-29-21 07:00AM	Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021 (PR Newswire)
Jun-15-21 11:37AM	2 Strong Buy Biotech Stocks That Can Inject a Healthy Dose of Upside (TipRanks)
May-26-21 07:00AM	Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021 (PR Newswire) +5.65%
May-12-21 07:00AM	Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results (PR Newswire)
May-03-21 07:00AM	Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer (PR Newswire)
Apr-06-21 07:00AM	Cogent Biosciences Announces Creation of Cogent Research Team (PR Newswire)
Mar-17-21 02:27AM	Do Institutions Own Cogent Biosciences, Inc. (NASDAQ:COGT) Shares? (Simply Wall St.)
Mar-16-21 07:00AM	Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results (PR Newswire) +6.72%
Feb-22-21 07:00AM	Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors (PR Newswire) -5.60%
Feb-18-21 07:00AM	Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021 (PR Newswire)
Feb-11-21 07:00AM	Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021 (PR Newswire)
Dec-04-20 05:16PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares (PR Newswire)
Dec-01-20 11:08PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock (PR Newswire) +6.73% +16.62%
Nov-30-20 04:01PM	Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock (PR Newswire)
07:00AM	Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer (PR Newswire)
Nov-20-20 07:00AM	Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference (PR Newswire)

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COGT

Cogent Biosciences Inc

Upgrade your FINVIZ experience